Anti-inflammatory Compound Development For The Treatment Of Heart Failure With Preserved Ejection Fraction
Funder
National Health and Medical Research Council
Funding Amount
$674,659.00
Summary
Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent and rapidly growing heart condition with no proven effective therapies. We will develop novel drugs to treat HFpEF by focussing on heart scarring and inflammation. We have promising drug candidates that will be developed during the project, and these will be ready for for phase I clinical trial by the end of this grant. The outcome of this study is poised to address the significant unmet medical need.
A Fully Implantable Self Powered Extra Aortic Counterpulsation Device? For Translational Development In Hypertensive Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$901,586.00
Summary
The development of a low cost self-powered cardiac aortic assist device to improve blood flow to the heart and rest of the body. The device is placed on the external surface of the large blood vessel (aorta) leaving the heart and provides gentle counterpulsation to improve blood flow. This aortic cardiac assist device is a therapeutic treatment for early stage heart failure.
Abnormal growth of blood vessels is a central feature of number of blinding conditions of the eye. Although there are treatments available that reduce the sudden loos of vision in a majority of people with advanced age related macular degeneration, about 20% fail to respond and half gradually loose vision. This project will determine the effectiveness of treating vascular diseases of the retina with a novel therapy that is quite different to that currently available.
Development Of A First-in-class Therapeutic For Protecting The Ischemic Heart
Funder
National Health and Medical Research Council
Funding Amount
$926,673.00
Summary
Heart disease is the leading cause of death globally. Heart attacks are the primary cause of death associated with heart disease. We have discovered a drug, Hi1a, that blocks the injury response of the heart when a heart attack happens. There are no other drugs currently available or in the discovery pipeline that address this problem. This proposal will use models of injury to the heart as well as safety studies to help develop Hi1a as a new drug for people who suffer from heart attacks.
Targeting Cystic Fibrosis Using A Novel Inhalation Therapy
Funder
National Health and Medical Research Council
Funding Amount
$421,545.00
Summary
Currently treatments for cystic fibrosis infection are via oral, intravenous or lengthy inhalation processes. This can lead to significant side effects, consequent poor patient compliance, and limited therapeutic efficacy. We will develop and test a novel high-dose inhalation dry power device containing an antibiotics for the rapid treatment of infection in cystic fibrosis therapy.
Development Of Microscope-in-a-needle Devices For Improved Clinical Diagnostics
Funder
National Health and Medical Research Council
Funding Amount
$327,746.00
Summary
We have developed a new high-resolution optical imaging technology. The unique aspect of our research has been to redesign the imaging probe, miniaturising it to a few hundred microns in diameter, and encase it in a hypodermic needle – a ‘microscope-in-a-needle’. We are developing specific imaging probes to aid in the assessment of lung disease; the diagnosis of liver disease; and integrated into a brain biopsy needle to enable safer brain biopsies.
From The Synchrotron To The Clinic: Translation Of A Novel Functional Lung Imaging Technology
Funder
National Health and Medical Research Council
Funding Amount
$891,834.00
Summary
Our team has recently developed a synchrotron technology with a startling capacity for dynamic functional imaging that can act as a sensitive regional indicator of lung disease. We will demonstrate that this technology can be translated from the synchrotron to the lab and eventually the clinic. We will provide proof of this concept by the application of this technology to emphysema, asthma, lung cancer, cystic fibrosis lung disease and neonatal resuscitation.